Literature DB >> 23439756

Temporal trends in mortality from diseases of the circulatory system after treatment for Hodgkin lymphoma: a population-based cohort study in Sweden (1973 to 2006).

Sandra Eloranta1, Paul C Lambert, Jan Sjöberg, Therese M L Andersson, Magnus Björkholm, Paul W Dickman.   

Abstract

PURPOSE: Hodgkin lymphoma (HL) survival in Sweden has improved dramatically over the last 40 years, but little is known about the extent to which efforts aimed at reducing long-term treatment-related mortality have contributed to the improved prognosis.
METHODS: We used population-based data from Sweden to estimate the contribution of treatment-related mortality caused by diseases of the circulatory system (DCS) to temporal trends in excess HL mortality among 5,462 patients diagnosed at ages 19 to 80 between 1973 and 2006. Flexible parametric survival models were used to estimate excess mortality. In addition, we used recent advances in statistical methodology to estimate excess mortality in the presence of competing causes of death.
RESULTS: Excess DCS mortality within 20 years after diagnosis has decreased continually since the mid-1980s and is expected to further decrease among patients diagnosed in the modern era. Age at diagnosis and sex were important predictors for excess DCS mortality, with advanced age and male sex being associated with higher excess DCS mortality. However, when accounting for competing causes of death, we found that excess DCS mortality constitutes a relatively small proportion of the overall mortality among patients with HL in Sweden.
CONCLUSION: Excess DCS mortality is no longer a common source of mortality among Swedish patients with HL. The main causes of death among long-term survivors today are causes other than HL, although other (non-DCS) excess mortality also persists for as long as 20 years after diagnosis, particularly among older patients.

Entities:  

Mesh:

Year:  2013        PMID: 23439756     DOI: 10.1200/JCO.2012.45.2714

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  5 in total

1.  Cause-Specific Mortality Following Initial Chemotherapy in a Population-Based Cohort of Patients With Classical Hodgkin Lymphoma, 2000-2016.

Authors:  Graça M Dores; Rochelle E Curtis; Nicole H Dalal; Martha S Linet; Lindsay M Morton
Journal:  J Clin Oncol       Date:  2020-09-18       Impact factor: 44.544

2.  Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era.

Authors:  Nicholas J Boddicker; Melissa C Larson; Alessia Castellino; Joerg Herrmann; David J Inwards; Gita Thanarajasingam; Matthew J Maurer; Cristine Allmer; Thomas E Witzig; Grzegorz S Nowakowski; Thomas M Habermann; Hector R Villarraga; Susan L Slager; James R Cerhan; Carrie A Thompson
Journal:  Am J Hematol       Date:  2021-05-27       Impact factor: 13.265

3.  Long-term risk of cardiovascular mortality in lymphoma survivors: A systematic review and meta-analysis.

Authors:  Devon J Boyne; Alexis T Mickle; Darren R Brenner; Christine M Friedenreich; Winson Y Cheung; Karen L Tang; Todd A Wilson; Diane L Lorenzetti; Matthew T James; Paul E Ronksley; Doreen M Rabi
Journal:  Cancer Med       Date:  2018-08-15       Impact factor: 4.452

4.  Distribution of hospital care among pediatric and young adult Hodgkin lymphoma survivors-A population-based cohort study from Sweden and Denmark.

Authors:  Ingrid Glimelius; Annika Englund; Klaus Rostgaard; Karin E Smedby; Sandra Eloranta; Peter de Nully Brown; Christoffer Johansen; Peter Kamper; Gustaf Ljungman; Lisa Lyngsie Hjalgrim; Henrik Hjalgrim
Journal:  Cancer Med       Date:  2019-07-02       Impact factor: 4.452

5.  Estimating causal effects in the presence of competing events using regression standardisation with the Stata command standsurv.

Authors:  Elisavet Syriopoulou; Sarwar I Mozumder; Mark J Rutherford; Paul C Lambert
Journal:  BMC Med Res Methodol       Date:  2022-08-13       Impact factor: 4.612

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.